Table 2.
Statistical correlation between H3K27me3 immunoexpression and clinical–pathological features of 34 intracranial meningiomas with evaluable H3K27me3 immunostaining.
| Parameter | H3K27me3 Immuno-Expression | p | |
|---|---|---|---|
| Lost | Retained | ||
| Sex | |||
| Male | 3 | 4 | |
| Female | 4 | 8 | 0.1811 |
| Age | |||
| <65 years | 3 | 12 | |
| ≥65 years | 4 | 15 | 0.9408 |
| Site | |||
| Sagittal | 2 | 12 | |
| Convexity | 3 | 9 | |
| Skull base | 2 | 4 | |
| Intraventricular | 0 | 2 | 0.6599 |
| WHO grade | |||
| 1 | 1 | 4 | |
| 2 | 6 | 23 | 0.9723 |
| Post-SRS tumor progression | |||
| Absent | 1 | 18 | |
| Present | 6 | 9 | 0.0143 |
| SRS | |||
| Adjuvant | 2 | 8 | |
| Salvage-residual | 1 | 10 | |
| Salvage-recurrent | 4 | 9 | 0.4241 |
| Treated tumor | |||
| Residual | 3 | 18 | |
| Recurrence | 4 | 9 | 0.2551 |
| Post-SRS recurrence | |||
| Edge of field | 1 | 2 | |
| In-field | 2 | 2 | |
| Out-of-field | 3 | 5 | 0.8856 |
SRS: stereotactic radiosurgery.